Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0.3	3.94	2.3	4.51
Revenue Growth (YoY)	-	-	-92.47%	71.69%	-49.06%	-
Gross Profit	0	0	0.3	3.94	2.3	4.51
Selling, General & Admin	8.83	8.13	12.86	20.62	28.82	34.4
Research & Development	1.53	1.52	5.98	37.64	56.41	95.14
Other Operating Expenses	3.3	3.3	0	0.88	-1.67	0
Operating Expenses	13.67	12.95	18.84	59.14	83.56	129.54
Operating Income	-13.67	-12.95	-18.54	-55.2	-81.27	-125.04
Interest Expense / Income	-0.35	-0.36	-0.29	0.02	-0.59	-2.03
Other Expense / Income	-13.47	-7.33	25.83	-3.56	-2.88	-
Pretax Income	0.15	-5.26	-44.08	-51.65	-77.8	-123.01
Net Income	0.15	-5.26	-44.08	-51.65	-77.8	-123.01
Shares Outstanding (Basic)	2	2	2	2	2	1
Shares Outstanding (Diluted)	-	2	2	-	-	-
Shares Change	14.61%	7.59%	0.33%	27.54%	23.64%	76.59%
EPS (Basic)	-0.04	-2.25	-20.28	-26.40	-51.20	-89.80
EPS (Diluted)	-0.43	-2.25	-20.28	-26.40	-51.20	-89.80
Free Cash Flow	-16.9	-21.25	-40.61	-35.06	-72.47	-108.93
Free Cash Flow Per Share	-6.78	-9.09	-18.69	-16.19	-42.68	-79.31
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-6242.42%	-1400.18%	-3539.42%	-2774.28%
Profit Margin	-	-	-14841.08%	-1310.17%	-3388.59%	-2729.27%
Free Cash Flow Margin	-	-	-13673.74%	-889.40%	-3156.45%	-2416.91%
EBITDA	-0.2	-5.62	-44.31	-51.16	-76.09	-122.34
EBITDA Margin	-	-	-14918.18%	-1297.79%	-3314.16%	-2714.38%
Depreciation & Amortization	0	0	0.07	0.47	2.3	2.7
EBIT	-0.2	-5.62	-44.37	-51.63	-78.39	-125.04
EBIT Margin	-	-	-14940.07%	-1309.77%	-3414.20%	-2774.28%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).